17	50	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'textual-organization', 'direction':'None', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Introduction'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 6), 'text':'Class IA PI3Ks transduce growth factor signalling'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(1, 7), 'end':(1, 18), 'text':'by phosphorylating phosphatidylinositol 4,5-bisphosphate ( PtdIns ( 4,5 ) P 2 )'}, {'start':(1, 19), 'end':(1, 31), 'text':'to produce PtdIns ( 3,4,5 ) P 3 on the plasma membrane .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 17), 'text':'Recruitment to membrane receptors and enzyme activation are coordinated by engagement of the p85 SH2 domains to regions'}, {'start':(2, 18), 'end':(2, 31), 'text':'bearing phosphorylated \' YXXM \' motifs on activated RTKs or RTK associated adaptors .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 13), 'text':'PtdIns ( 3,4,5 ) P 3 serves as docking sites for downstream signalling molecules'}, {'start':(3, 14), 'end':(3, 19), 'text':'that harbour pleckstrin homology domains .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 9), 'text':'Central among these are PDK1 and PKB and AKT ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 10), 'end':(4, 13), 'text':'which orchestrate signalling cascades'}, {'start':(4, 14), 'end':(4, 25), 'text':'promoting cell growth , proliferation , survival , metabolism and migration .'}]}]}, {'start':(5, 0), 'end':(5, 12), 'text':'Cellular levels of PtdIns ( 3,4,5 ) P 3 are tightly regulated .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 3), 'text':'PTEN down-regulates p110 signalling'}, {'start':(6, 4), 'end':(6, 20), 'text':'by removing the 3 \' - phosphate of PtdIns ( 3,4,5 ) P 3 ( ) .'}]}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 27), 'text':'Up regulation of PI3K signalling , through amplification or gain-of-function mutations of RTKs , p110alpha and AKTs , as well as loss of PTEN function and expression ,'}, {'start':(7, 28), 'end':(7, 33), 'text':'occurs frequently in human cancers .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 7), 'text':'Uniquely among the four class I PI3K isoforms'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 8), 'end':(8, 23), 'text':'that produce PtdIns ( 3,4,5 ) P 3 , p110alpha has been identified with activating cancer'}, {'start':(8, 24), 'end':(8, 29), 'text':'linked somatic mutations ( ) .'}]}]}, {'start':(9, 0), 'end':(9, 28), 'text':'Over 80 % of the missense mutations cluster in two \' hotspots \' commonly represented by E545K in the helical domain , and H1047R in the kinase domain .'}]}, {'start':(10, 0), 'end':(10, 7), 'text':'Both display transforming activities in cell culture .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 1), 'text':'The ability'}, {'start':(11, 2), 'end':(11, 16), 'text':'to initiate tumorigenesis in transgenic mouse models has been demonstrated for the H1047R mutant .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 15), 'text':'Crystal structures of p110alpha and 85alpha complexes have provided molecular details of p85 mediated inhibition ,'}, {'start':(12, 16), 'end':(12, 16), 'text':'revealing'}]}, {'start':(12, 17), 'end':(12, 21), 'text':'that many activating mutations ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 22), 'end':(12, 23), 'text':'including ones'}, {'start':(12, 24), 'end':(12, 28), 'text':'occurring at low frequencies ,'}]}]}, {'start':(12, 29), 'end':(12, 35), 'text':'are located in inter-domain contact sites .'}]}, {'start':(13, 0), 'end':(13, 30), 'text':'These sites include the inhibitory interfaces between the p110alpha C2/helical/kinase domains and the p85alpha nSH2 domain , and between the p110alpha C2 domain and the p85alpha iSH2 domain ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 11), 'text':'Phosphopeptide binding to nSH2 competes with its inhibitory interaction with p110 ,'}, {'start':(14, 12), 'end':(14, 25), 'text':'constituting the dominant activation mechanism for p110alpha , and E545K mimics this activation .'}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 13), 'text':'Since p110alpha adaptor binding domain ( ABD ) binds to p85alpha iSH2 tightly ,'}, {'start':(15, 14), 'end':(15, 35), 'text':'the often mutated interface between ABD and the kinase domain can be viewed as an extension of the p85 inhibitory network .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 13), 'text':'Mutations in the kinase C-terminal region do not appear to interfere with p85 inhibition'}, {'start':(16, 14), 'end':(16, 28), 'text':'since p85alpha cSH2 does not play an inhibitory role in p110alpha regulation ( ) ,'}]}, {'start':(16, 29), 'end':(16, 42), 'text':'although it does for p110beta and p110delta via direct contact with this region .'}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 3), 'text':'Some of the cancer'}, {'start':(17, 4), 'end':(17, 18), 'text':'linked mutations confer a positive charge , such as C420R and H1047R in p110alpha ,'}]}, {'start':(17, 19), 'end':(17, 27), 'text':'and have been suggested to enhance membrane binding .'}]}, {'start':(18, 0), 'end':(18, 8), 'text':'However , direct membrane binding measurements are lacking .'}]}, {'start':(19, 0), 'end':(19, 14), 'text':'A common assumption is that these mutations directly facilitate electrostatic interaction with phospholipid headgroups .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 13), 'text':'However , this has limited applicability to other activating mutations , notably H1047L .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(21, 0), 'end':(21, 19), 'text':'The E545K and H1047R mutants were first reported to have similar biological activities , in terms of promoting cell growth'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 20), 'end':(21, 25), 'text':'and resisting apoptosis under growth factor'}, {'start':(21, 26), 'end':(21, 30), 'text':'limiting conditions ( ) .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(22, 0), 'end':(22, 3), 'text':'More recent studies showed'}, {'label':'joint', 'direction':'None', 'children':[{'start':(22, 4), 'end':(22, 20), 'text':'that they can have differential functional outcomes , in terms of chemotactic and metastatic phenotypes ( )'}, {'start':(22, 21), 'end':(22, 32), 'text':'and transforming potential ( ) of isogenic human breast cancer cells .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 14), 'text':'Transforming ability of chicken embryonic fibroblasts differs between the E545K and the H1047R mutants ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 15), 'end':(23, 17), 'text':'invoking the suggestion'}, {'start':(23, 18), 'end':(23, 29), 'text':'that these two mutants operate via different activation mechanisms ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(24, 0), 'end':(24, 17), 'text':'Previously , the E545K and H1047R mutants were found to be more active than the WT enzyme ,'}, {'start':(24, 18), 'end':(24, 35), 'text':'but their similar affinities for ATP did not explain the differences in lipid kinase activities ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 5), 'text':'Here , we investigated the premise'}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(25, 6), 'end':(25, 17), 'text':'that enhanced lipid binding forms a general mechanism for p110 activation ,'}, {'start':(25, 18), 'end':(25, 22), 'text':'particularly regarding cancer mutations .'}]}]}, {'start':(26, 0), 'end':(26, 9), 'text':'We dissected the structural elements important for lipid binding .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(27, 0), 'end':(27, 2), 'text':'Our results show'}, {'start':(27, 3), 'end':(27, 28), 'text':'that p85alpha nSH2 , a key regulatory element for p110alpha lipid kinase activity , controls access of the catalytic subunit lipid binding sites to membrane .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 8), 'text':'We examined a set of p110alpha and p85alpha cancer'}, {'start':(28, 9), 'end':(28, 17), 'text':'linked mutants of diverse structural and chemical types ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 18), 'end':(28, 22), 'text':'and find a strong correlation'}, {'start':(28, 23), 'end':(28, 34), 'text':'linking their elevated lipid kinase activities to their lipid binding levels .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 16), 'text':'We present a crystal structure of WT p110alpha and p85alpha-iSH 2 in complex with an inhibitor .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 12), 'text':'Its structural features in the kinase domain resemble those of the H1047R mutant'}, {'start':(30, 13), 'end':(30, 24), 'text':'( ) , instead of the WT apo structure ( ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(31, 0), 'end':(31, 10), 'text':'We also noted unusual structural features of the kinase C-terminal tail'}, {'start':(31, 11), 'end':(31, 15), 'text':'and tested their function .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 4), 'text':'We observe global conformational changes'}, {'start':(32, 5), 'end':(32, 15), 'text':'that might be of relevance to allosteric regulation of p110alpha ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 16), 'end':(32, 20), 'text':'and provide a structural context'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 21), 'end':(32, 25), 'text':'to understand the functional data'}, {'start':(32, 26), 'end':(32, 28), 'text':'presented here .'}]}]}]}]}]}]}]}]}]}]}
0	1	{'start':(0, 0), 'end':(0, 11), 'text':'Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases'}
238	239	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Material'}
1	17	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 5), 'text':'Somatic missense mutations in PIK3CA ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 6), 'end':(0, 14), 'text':'which encodes the p110alpha catalytic subunit of phosphoinositide 3-kinases'}, {'start':(0, 15), 'end':(0, 18), 'text':'( PI3Ks ) ,'}]}]}, {'start':(0, 19), 'end':(0, 24), 'text':'occur frequently in human cancers .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 1), 'text':'Activating mutations'}, {'start':(1, 2), 'end':(1, 6), 'text':'spread across multiple domains ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 7), 'end':(1, 15), 'text':'some of which are located at inhibitory contact sites'}, {'start':(1, 16), 'end':(1, 22), 'text':'formed with the regulatory subunit p85alpha .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 1), 'text':'PIK3R1 ,'}, {'start':(2, 2), 'end':(2, 5), 'text':'which encodes p85alpha ,'}]}, {'start':(2, 6), 'end':(2, 11), 'text':'also has activating somatic mutations .'}]}, {'start':(3, 0), 'end':(3, 31), 'text':'We find a strong correlation between lipid kinase and lipid binding activities , for both wild-type ( WT ) and a representative set of oncogenic mutant complexes of p110alpha and p85alpha .'}]}]}, {'start':(4, 0), 'end':(4, 8), 'text':'Lipid binding involves both electrostatic and hydrophobic interactions .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 0), 'text':'Activation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 1), 'end':(5, 18), 'text':'caused by a phosphorylated receptor tyrosine kinase ( RTK ) peptide binding to the p85alpha N-terminal SH2 domain'}, {'start':(5, 19), 'end':(5, 25), 'text':'( nSH2 ) induces lipid binding .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 10), 'text':'This depends on the polybasic activation loop as well as a'}, {'start':(6, 11), 'end':(6, 22), 'text':'conserved hydrophobic motif in the C-terminal region of the kinase domain .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 10), 'text':'The hotspot E545K mutant largely mimics the activated WT p110alpha .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(8, 0), 'end':(8, 9), 'text':'It shows the highest basal activity and lipid binding ,'}, {'start':(8, 10), 'end':(8, 19), 'text':'and is not significantly activated by an RTK phosphopeptide .'}]}]}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(9, 0), 'end':(9, 18), 'text':'Both the hotspot H1047R mutant and rare mutations ( C420R , M1043I , H1047L , G1049R and p85alpha-N564D )'}, {'start':(9, 19), 'end':(9, 28), 'text':'also show increased basal kinase activities and lipid binding .'}]}, {'start':(10, 0), 'end':(10, 20), 'text':'However , their activities are further enhanced by an RTK phosphopeptide to levels markedly exceeding that of activated WT p110alpha .'}]}]}, {'start':(11, 0), 'end':(11, 16), 'text':'Phosphopeptide binding to p110beta and p85alpha and p110delta and p85alpha complexes also induces their lipid binding .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 7), 'text':'We present a crystal structure of WT p110alpha'}, {'start':(12, 8), 'end':(12, 21), 'text':'complexed with the p85alpha inter-SH2 domain ( iSH2 ) and the inhibitor PIK-108 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 20), 'text':'Additional to the ATP binding pocket , an unexpected , second PIK-108 binding site is observed in the kinase C-lobe .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 18), 'text':'We show a global conformational change in p110alpha consistent with allosteric regulation of the kinase domain by nSH2 .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 15), 'text':'These findings broaden our understanding of the differential biological outputs exhibited by distinct types of mutations'}, {'start':(15, 16), 'end':(15, 20), 'text':'regarding growth factor dependence ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 21), 'end':(15, 26), 'text':'and suggest a two-tier classification scheme'}, {'start':(15, 27), 'end':(15, 35), 'text':'relating p110alpha and p85alpha mutations with signalling potential .'}]}]}]}]}]}]}
203	238	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 2), 'text':'Materials and methods'}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 0), 'text':'Plasmids'}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 25), 'text':'Details of expression constructs for p110alpha , p110beta , p110delta ( all mouse ) , p85alpha ( mouse , except for the \' ni \' fragment'}, {'start':(2, 26), 'end':(2, 30), 'text':'which is human ) ,'}]}, {'start':(2, 31), 'end':(2, 39), 'text':'and Grp1-PH ( human ) are provided in .'}]}, {'start':(3, 0), 'end':(3, 8), 'text':'Domain boundaries of p85alpha fragments are shown in .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 3), 'text':'Protein expression and purification'}, {'start':(5, 0), 'end':(5, 11), 'text':'All p110 and p85 complexes were co-expressed in Sf9 insect cells .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 10), 'text':'The N-terminal His 6 -tag on p110alpha was kept for proteins'}, {'start':(6, 11), 'end':(6, 13), 'text':'used for crystallization'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 14), 'end':(6, 19), 'text':'but was cleaved off for those'}, {'start':(6, 20), 'end':(6, 24), 'text':'used for functional analyses .'}]}]}, {'start':(7, 0), 'end':(7, 6), 'text':'GST-Grp1-PH was expressed in E coli .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 8), 'text':'Details of expression and purification are described in .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 3), 'text':'Crystallization and structure determination'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 9), 'text':'The complex of His 6 - ( TEV ) -'}, {'start':(10, 10), 'end':(10, 20), 'text':'tagged mouse p110alpha with human p85alpha-niSH2 was co-crystallized with PIK-108 .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(11, 0), 'end':(11, 6), 'text':'The crystals diffracted to 3.5 A ,'}, {'start':(11, 7), 'end':(11, 19), 'text':'and belong to the spacegroup I222 with one heterodimer per asymmetric unit .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 12), 'text':'The human apo WT p110alpha and p85alpha-iSH 2 structure , PDB ID :'}, {'start':(12, 13), 'end':(12, 24), 'text':'2rd0 ) was used as the search model for molecular replacement .'}]}, {'start':(13, 0), 'end':(13, 9), 'text':'Details of crystallization and structure determination are described in .'}]}, {'start':(14, 0), 'end':(14, 5), 'text':'Crystallographic statistics are presented in .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 6), 'text':'All structural graphics were prepared with PyMOL'}, {'start':(15, 7), 'end':(15, 10), 'text':'( www.pymol.org ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 3), 'text':'Lipid kinase activity assay'}, {'start':(17, 0), 'end':(17, 0), 'text':'Liposomes'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 1), 'end':(17, 2), 'text':'comprising PC/PE/PS'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 3), 'end':(17, 11), 'text':'/ PtdIns ( 4,5 ) P 2 / cholesterol'}, {'start':(17, 12), 'end':(17, 22), 'text':'were in mol % ratios of either 38:25:20:2:15 or 38:35:10:2:15 .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 35), 'text':'PtdIns ( 3,4,5 ) P 3 production was measured by a modified fluorescence polarization assay ( Echelon Biosciences ) originally developed for use with diC8-PtdIns ( 4,5 ) P 2 as a substrate ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 15), 'text':'Reactions were carried out at room temperature ( 25 degreesC ) in 384-well microtitre plates .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 8), 'text':'A 10 mul reaction consisted of 50 muM PtdIns'}, {'start':(20, 9), 'end':(20, 57), 'text':'( 4,5 ) P 2 in 2.5 mM liposomes , p110 and p85 ( 500 nM for non activated WT p110alpha and p85alpha-nicSH 2 , 5 nM for the rest ) , 100 muM ATP , 1 mM MgCl 2 , and with or without 1 muM pY2-peptide .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 7), 'text':'The reactions were quenched with 5 mul buffer'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 8), 'end':(21, 29), 'text':'containing 20 mM Hepes ( pH 7.5 ) , 150 mM NaCl , 20 mM EDTA , and 400 nM GST-Grp1-PH ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 30), 'end':(21, 39), 'text':'followed by addition of 5 mul of 40 nM TAMRA-Ins'}, {'start':(21, 40), 'end':(21, 48), 'text':'( 1,3,4,5 ) P 4 in HNT buffer .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 13), 'text':'The plates were read in a PHERAstar spectrofluorometer ( BMG Labtech , Germany )'}, {'start':(22, 14), 'end':(22, 27), 'text':'using the FP and 540 -20 / 590-20 and 590 -20 optical module .'}]}]}]}, {'start':(23, 0), 'end':(23, 15), 'text':'Standard curves were performed with diC8-PtdIns ( 3,4,5 ) P 3 with or without pY2-peptide .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 15), 'text':'Only a minor difference due to presence of pY2-peptide was observed under our assay condition ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 16), 'end':(24, 20), 'text':'which is different from that'}, {'start':(24, 21), 'end':(24, 25), 'text':'published previously ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 4), 'text':'SPR measurement of lipid binding'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 11), 'text':'Liposome binding experiments were performed at 25 degreesC on a BIAcore2000 ,'}, {'start':(26, 12), 'end':(26, 21), 'text':'using the L1 sensor chip ( GE Healthcare ) .'}]}]}, {'start':(27, 0), 'end':(27, 7), 'text':'HNT was used as the running buffer .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 0), 'text':'Liposomes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 1), 'end':(28, 2), 'text':'comprising PC/PE/PS'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 3), 'end':(28, 11), 'text':'/ PtdIns ( 4,5 ) P 2 / cholesterol'}, {'start':(28, 12), 'end':(28, 38), 'text':'were in mol % ratios of either 60:25:0:0:15 ( Fc1 ) , 50:25:10:0:15 ( Fc2 ) , 48:25:10:2:15 ( Fc3 ) or 38:25:20:2:15 ( Fc4 ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(29, 0), 'end':(29, 6), 'text':'Liposomes ( 0.1 - 0.2 mM )'}, {'start':(29, 7), 'end':(29, 26), 'text':'were injected onto each flow-cell at 5 mul and min flow rate to achieve ~ 3400 RU immobilization level .'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 12), 'text':'This was followed by two injections of 0.2 M Na 2 CO 3'}, {'start':(30, 13), 'end':(30, 18), 'text':'to remove loosely bound liposomes .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(31, 0), 'end':(31, 9), 'text':'Chicken egg white albumin ( 0.2 mg and ml )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 10), 'end':(31, 20), 'text':'was injected over the flow-cells to mask any residual hydrophobic surface'}, {'start':(31, 21), 'end':(31, 26), 'text':'not covered by the liposomes ,'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(31, 27), 'end':(31, 37), 'text':'followed by multiple injections of 0.2 M Na 2 CO 3'}, {'start':(31, 38), 'end':(31, 42), 'text':'to stabilize the baseline .'}]}]}]}, {'start':(32, 0), 'end':(32, 30), 'text':'Steady-state binding was measured by injecting p110 and p85 complexes ( concentration at either 500 nM or 1 muM ) at 2 mul and min flow rate for 5 min .'}]}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 12), 'text':'Each measurement was followed by injections of 0.2 M Na 2 CO 3'}, {'start':(33, 13), 'end':(33, 18), 'text':'to regenerate the liposome surface .'}]}]}]}]}]}]}]}]}]}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 8), 'text':'Independent experiments were carried out with freshly immobilized liposomes'}, {'start':(34, 9), 'end':(34, 32), 'text':'after stripping the sensor surface sequentially with 0.1 N NaOH , isopropanol :0.1 N NaOH ( 2:3 ) and 6 M guanidinium HCl .'}]}]}
239	240	{'start':(0, 0), 'end':(0, 0), 'text':'1'}
156	203	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Discussion'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(1, 0), 'end':(1, 3), 'text':'We have directly demonstrated'}, {'start':(1, 4), 'end':(1, 18), 'text':'that phosphopeptide induced lipid binding underlies the activation mechanism for WT p110alpha and p85alpha .'}]}]}, {'start':(2, 0), 'end':(2, 19), 'text':'For most cancer linked mutants of p110alpha and p85alpha , both basal and phosphopeptide induced membrane binding is enhanced .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 14), 'text':'For WT p110alpha , the primary lipid binding sites reside in the kinase domain ,'}, {'start':(3, 15), 'end':(3, 27), 'text':'comprising the polybasic activation loop and hydrophobic elements in the C-terminal tail .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 22), 'text':'We have identified activating cancer linked mutants in the kinase C-terminal tail ( H1047L , H1047R , G1049R ) as well as mutants'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 23), 'end':(4, 26), 'text':'affecting the C2-iSH2 interaction'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 27), 'end':(4, 31), 'text':'( C420R and p85alpha-N564D )'}, {'start':(4, 32), 'end':(4, 37), 'text':'that enhance intrinsic lipid binding .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 13), 'text':'Our binding data and structural analysis support the dual roles of C420R and N564D'}, {'label':'joint', 'direction':'None', 'children':[{'start':(5, 14), 'end':(5, 17), 'text':'in disrupting C2-iSH2 contact'}, {'start':(5, 18), 'end':(5, 22), 'text':'and enhancing lipid binding .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(6, 0), 'end':(6, 2), 'text':'It is likely'}, {'start':(6, 3), 'end':(6, 20), 'text':'that this occurs via direct interactions between the C2 and and or the iSH2 domains with membranes .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 10), 'text':'This additional membrane binding site could both enhance total lipid binding'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 11), 'end':(7, 17), 'text':'and influence the choice of the membrane'}, {'start':(7, 18), 'end':(7, 34), 'text':'used by the WT enzyme or by particular p110alpha and p85alpha mutants in a cellular context .'}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(8, 0), 'end':(8, 2), 'text':'Our data indicate'}, {'label':'joint', 'direction':'None', 'children':[{'start':(8, 3), 'end':(8, 10), 'text':'that the inhibitory contact formed between the nSH2'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(8, 11), 'end':(8, 19), 'text':'and p110alpha C2/helical/kinase domains suppresses the basal kinase activity'}, {'start':(8, 20), 'end':(8, 24), 'text':'by inhibiting membrane binding .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 12), 'text':'This is consistent with previous biochemical results for enzyme activity ( ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 13), 'end':(9, 27), 'text':'in that the p85alpha nSH2 , but not the cSH2 , plays a principal role'}, {'start':(9, 28), 'end':(9, 34), 'text':'in regulating the activity of p110alpha .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(10, 0), 'end':(10, 3), 'text':'Mechanistically , we postulate'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 4), 'end':(10, 18), 'text':'that relieving the nSH2 inhibitory contact from p110alpha could result in a concerted conformational change'}, {'start':(10, 19), 'end':(10, 28), 'text':'propagating from the helical domain to the kinase C-lobe ,'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(10, 29), 'end':(10, 36), 'text':'as suggested by our structural comparison of activated'}, {'start':(10, 37), 'end':(10, 46), 'text':'and inhibited forms of p110alpha and p85alpha ( ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 9), 'text':'This might trigger the activation loop and the C-terminal region'}, {'start':(11, 10), 'end':(11, 16), 'text':'to adopt lipid binding competent conformations .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 0), 'end':(12, 13), 'text':'The polybasic activation loop both facilitates long range electrostatic attraction to anionic lipids ,'}, {'start':(12, 14), 'end':(12, 31), 'text':'and positions the PtdIns ( 4,5 ) P 2 headgroup to the bound ATP for phosphoryl transfer .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(13, 0), 'end':(13, 11), 'text':'Since the ATP binding pocket is recessed in the kinase domain ,'}, {'start':(13, 12), 'end':(13, 39), 'text':'partial membrane penetration by the C-terminal region would facilitate approach of the ATP gamma-phosphate to the inositol ring of PtdIns ( 4,5 ) P 2 ( ) .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(14, 0), 'end':(14, 2), 'text':'We have demonstrated'}, {'start':(14, 3), 'end':(14, 21), 'text':'that binding of activated p110 and p85alpha to lipid membrane has both an electrostatic and a hydrophobic component .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 11), 'text':'Basic residues in the activation loop contribute to the electrostatic component .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(16, 0), 'end':(16, 9), 'text':'The C-terminal tail is clearly important for membrane interaction ,'}, {'start':(16, 10), 'end':(16, 15), 'text':'but its contribution is complex .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(17, 0), 'end':(17, 2), 'text':'SPR measurements show'}, {'start':(17, 3), 'end':(17, 20), 'text':'that mutating the hydrophobic WIF motif to " AAA " abolishes measureable electrostatic interactions with anionic lipids .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 18), 'text':'Conversely , the activated H1047L , H1047R and G1049R mutants increase both hydrophobic and electrostatic interactions with lipids .'}, {'start':(19, 0), 'end':(19, 31), 'text':'These observations attest to the importance of cooperation between the electrostatic and the hydrophobic membrane binding elements in p110alpha and p85alpha , as seen for other membrane binding proteins ( ) .'}]}]}]}]}]}, {'start':(20, 0), 'end':(20, 24), 'text':'Our data also elucidate the influence of lipid composition on lipid kinase activities for both WT and mutant p110 and p85 complexes ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 14), 'text':'Our structure reveals an alternative , small molecule binding site in the kinase C-lobe .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 12), 'text':'Current inhibitors for class I PI3K are all ATP-competitive compounds ( ) .'}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 13), 'text':'This induced binding pocket might be exploited to develop a novel class of inhibitors'}, {'start':(23, 14), 'end':(23, 18), 'text':'that are not ATP competitive'}]}, {'start':(23, 19), 'end':(23, 25), 'text':'but could interfere with membrane binding .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 11), 'text':'Although we could not detect any inhibition of lipid binding with PIK-108'}, {'start':(24, 12), 'end':(24, 21), 'text':'( up to 50 muM for the CD_E545K mutant ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 22), 'end':(24, 26), 'text':'assayed in the same manner'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 27), 'end':(24, 30), 'text':'described in , data'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(24, 31), 'end':(24, 34), 'text':'not shown ) ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(24, 35), 'end':(24, 37), 'text':'it might be'}, {'start':(24, 38), 'end':(24, 51), 'text':'that compounds with enhanced affinity for this site could act as PI3K inhibitors .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 6), 'text':'An example of a membrane binding inhibitor'}, {'start':(25, 7), 'end':(25, 11), 'text':'that is in clinical trials'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 12), 'end':(25, 16), 'text':'is Perifosine , an alkylphospholipid'}, {'start':(25, 17), 'end':(25, 26), 'text':'that targets the PH domain of AKT ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(26, 0), 'end':(26, 1), 'text':'It appears'}, {'start':(26, 2), 'end':(26, 15), 'text':'that the p110alpha and p85alpha mutations can be classified as two basic types :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 16), 'end':(26, 19), 'text':'( I ) those'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 20), 'end':(26, 29), 'text':'that relieve p85 mediated inhibition and ( II ) those'}, {'start':(26, 30), 'end':(26, 39), 'text':'that lead to additional lipid binding capability ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 6), 'text':'Type I mutations up regulate kinase activity'}, {'start':(27, 7), 'end':(27, 19), 'text':'by unmasking the intrinsic lipid binding potential of WT p110alpha and p85alpha .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(28, 0), 'end':(28, 5), 'text':'These mutants have elevated basal activities'}, {'start':(28, 6), 'end':(28, 23), 'text':'and binding of RTK phosphopeptides does not significantly enhance their activities beyond that of activated WT enzyme .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(29, 0), 'end':(29, 2), 'text':'We have shown'}, {'start':(29, 3), 'end':(29, 18), 'text':'that the hotspot mutant E545K belongs to this class , in accordance with previous work .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 3), 'text':'Several other activating mutations'}, {'start':(30, 4), 'end':(30, 32), 'text':'that are distant from the putative membrane interface , such as R38C and H , R88Q , P539R , and deletion of residues 449-455 in the C2beta7-beta8 loop ,'}]}, {'start':(30, 33), 'end':(30, 41), 'text':'could also belong to this class ( ) .'}]}]}, {'start':(31, 0), 'end':(31, 11), 'text':'Type II mutations are still subjected to p85alpha nSH2 mediated inhibition .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(32, 0), 'end':(32, 4), 'text':'We and others have shown'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 5), 'end':(32, 11), 'text':'that H1047R belongs to this type ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 12), 'end':(32, 21), 'text':'which can be significantly activated by a phosphorylated RTK peptide'}, {'start':(32, 22), 'end':(32, 33), 'text':'( this study ) or the adaptor protein IRS ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(33, 0), 'end':(33, 14), 'text':'Although basal activities of type II mutants are higher than that of WT enzyme ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 15), 'end':(33, 21), 'text':'their maximal lipid binding and kinase activities'}, {'start':(33, 22), 'end':(33, 43), 'text':'achieved by RTK phosphopeptide binding greatly exceed those of the activated WT enzyme ( 3-7 fold with our experimental setup ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(34, 0), 'end':(34, 4), 'text':'Our in vitro results imply'}, {'start':(34, 5), 'end':(34, 24), 'text':'that the biological outputs of the type II mutants can be greatly augmented by growth factor and RTK signalling .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 5), 'text':'This notion is supported by reports'}, {'start':(35, 6), 'end':(35, 15), 'text':'that compared the E545K and H1047R mutants in cells .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 3), 'text':'Human cancer cell lines'}, {'start':(36, 4), 'end':(36, 7), 'text':'bearing helical domain mutations'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 8), 'end':(36, 19), 'text':'showed lower AKT phosphorylation level and AKT dependent signalling than cell lines'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 20), 'end':(36, 23), 'text':'bearing kinase domain mutations'}, {'start':(36, 24), 'end':(36, 34), 'text':'coupled with either HER2 amplification or EGFR hyperactivation ( ) .'}]}]}]}]}]}]}]}, {'start':(37, 0), 'end':(37, 23), 'text':'H1047R , but not E545K , was found to enhance HER2 mediated transformation of breast cancer cells via autocrine proliferative stimulation ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 18), 'text':'Therefore , cancers with the type II mutations might be better treated by co-inhibition of p110alpha and RTKs ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(38, 19), 'end':(38, 26), 'text':'because these mutants strongly depend on RTK stimulation'}, {'start':(38, 27), 'end':(38, 40), 'text':'to reach a critical threshold of membrane binding and activity necessary for transformation .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 1), 'text':'For E545K'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 2), 'end':(39, 6), 'text':'to achieve a similar level'}, {'start':(39, 7), 'end':(39, 16), 'text':'of transforming activity as H1047R in chicken embryonic fibroblasts ,'}]}]}, {'start':(39, 17), 'end':(39, 24), 'text':'it required additionally Ras binding ( ) .'}]}, {'start':(40, 0), 'end':(40, 13), 'text':'It is likely that Ras could increase recruitment of p110alpha to lipid membrane .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(41, 0), 'end':(41, 21), 'text':'Cancers with type I mutations such as E545K might be better treated by co-inhibition of the p110alpha and the Ras pathway ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 22), 'end':(41, 34), 'text':'because these mutants could be more dependent on " topping-up " by Ras'}, {'start':(41, 35), 'end':(41, 44), 'text':'to achieve the membrane binding threshold necessary for transformation .'}]}]}, {'start':(42, 0), 'end':(42, 18), 'text':'Type I and type II mutants could also confer distinct functional significance during different stages of cancer biology .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 21), 'text':'For example , the E545K mutant was found to have a stronger metastatic phenotype than the H1047R mutant in tumor xenograft models'}, {'start':(43, 22), 'end':(43, 31), 'text':'using isogenic , human breast cancer cells ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 1), 'text':'The ability'}, {'start':(44, 2), 'end':(44, 31), 'text':'to induce tumour formation thus far has been demonstrated only for the H1047R mutant , but not yet for the E545K mutant , in engineered mouse models of cancers .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 10), 'text':'Both growth factor independence and growth factor signalling manipulation are traits'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(45, 11), 'end':(45, 14), 'text':'that enable cancer cells'}, {'start':(45, 15), 'end':(45, 19), 'text':'to sustain proliferative signalling .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(46, 0), 'end':(46, 25), 'text':'Investigating the influence of upstream RTK signalling could elucidate the yet unclear roles of the different PI3K mutations in cancer initiation , progression and maintenance ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 26), 'end':(46, 33), 'text':'and in identifying suitable biomarkers for cancer therapy'}, {'start':(46, 34), 'end':(46, 40), 'text':'targeting the PI3K pathway ( ) .'}]}]}]}]}
50	156	{'label':'topic-change', 'direction':'None', 'children':[{'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Results'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 8), 'text':'Structure of a wildtype p110alpha and p85alpha-iSH 2 complex'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 24), 'text':'A crystal structure of mouse WT p110alpha in complex with human p85alpha niSH2 fragment and the p110beta and p110delta selective inhibitor PIK-108 has been determined'}, {'start':(2, 25), 'end':(2, 38), 'text':'and refined to 3.5 A ( R work / R free = 0.184 /'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 39), 'end':(2, 40), 'text':'0.228 )'}, {'start':(2, 41), 'end':(2, 55), 'text':'( acronyms of p110alpha and p85alpha domain structures and mutations are illustrated in ) .'}]}]}]}, {'start':(3, 0), 'end':(3, 7), 'text':'Details of crystallographic statistics are provided in .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 2), 'text':'Although other compounds'}, {'start':(4, 3), 'end':(4, 12), 'text':'that inhibit p110alpha more specifically were surveyed for co-crystallization ,'}]}, {'start':(4, 13), 'end':(4, 23), 'text':'the p110beta and delta selective PIK-108 produced the best crystals .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 13), 'text':'As in the structure of human WT p110alpha and p85alpha-iSH 2 ( ) ,'}, {'start':(5, 14), 'end':(5, 29), 'text':'the nSH2 of the p85alpha niSH2 fragment is not observed in the electron density map .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 16), 'text':'The high salt concentration in the crystallization cocktail might have competed off nSH2 binding to p110alpha .'}, {'start':(7, 0), 'end':(7, 16), 'text':'As such , our structure represents an alternative view of p110alpha not constrained by nSH2 binding .'}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 8), 'text':'Unlike previous structures of p110alpha and p85alpha complexes ,'}, {'start':(8, 9), 'end':(8, 22), 'text':'our structure shows clear electron density for the entire activation loop ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 11), 'text':'However , key conserved activation loop residues , K942 and R949 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 12), 'end':(9, 18), 'text':'previously identified to be important for p110gamma'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 19), 'end':(9, 22), 'text':'recognising the substrate PtdIns'}, {'start':(9, 23), 'end':(9, 42), 'text':'( 4,5 ) P 2 head group ( ) , point away from the ATP binding site ( ) .'}]}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(10, 0), 'end':(10, 1), 'text':'Hence ,'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 2), 'end':(10, 16), 'text':'although structure of a p110alpha and p85alpha-iSH 2 complex should mimic an RTK activated state'}, {'start':(10, 17), 'end':(10, 21), 'text':'( see below ) ,'}]}, {'start':(10, 22), 'end':(10, 42), 'text':'the observed conformation of this loop does not appear to be compatible with positioning the lipid headgroup for phosphoryl transfer .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 11), 'text':'The activation loop is also involved in crystal contacts ( ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 12), 'end':(11, 16), 'text':'which likely influenced the conformation'}, {'start':(11, 17), 'end':(11, 19), 'text':'we observe .'}]}]}, {'start':(12, 0), 'end':(12, 10), 'text':'PIK-108 belongs to the class of propeller shaped PI3K inhibitors .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 18), 'text':'In our structure , the PIK-108 phenyl substituent occupies what has been coined the \' specificity pocket \' ,'}, {'start':(13, 19), 'end':(13, 35), 'text':'which is gated by the P-loop M772 , in the kinase ATP binding site ( ) .'}]}, {'start':(14, 0), 'end':(14, 22), 'text':'Opening of this pocket by propeller shaped compounds appears to be more favourable in p110delta than in other p110 isotypes ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 13), 'text':'This could be the reason for the PIK-108 selectivity for p110beta and p110delta .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 13), 'text':'There is also complete density for what we interpret as a second PIK-108 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 14), 'end':(16, 23), 'text':'snuggling in a hydrophobic pocket in the kinase C-lobe ,'}, {'start':(16, 24), 'end':(16, 40), 'text':'surrounded by helices kalpha6-8 , kalpha11 and the C-terminal end of the activation loop ( ) .'}]}]}, {'start':(17, 0), 'end':(17, 20), 'text':'This pocket is partially occupied by the activation loop residues 954-956 ( or their equivalents ) in other p110 structures .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 19), 'text':'The presence of the compound in this induced pocket may have contributed to the ordering of the activation loop ,'}, {'start':(18, 20), 'end':(18, 26), 'text':'which is involved in crystal packing ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(18, 27), 'end':(18, 29), 'text':'and might explain'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 30), 'end':(18, 41), 'text':'why this crystal form is specific to PIK-108 , out of twenty'}, {'start':(18, 42), 'end':(18, 46), 'text':'tested p110 selective inhibitors .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 8), 'text':'The kinase C-terminal region of p110alpha exhibits intrinsic flexibility'}, {'label':'contrast', 'direction':'None', 'children':[{'start':(20, 0), 'end':(20, 7), 'text':'Our structure is for the WT p110alpha ,'}, {'start':(20, 8), 'end':(20, 45), 'text':'but the kinase C-terminal tail more closely resembles those in the structures of the oncogenic mutant H1047R p110alpha and p85alpha-niSH 2 ( ) , than that in the WT apo p110alpha and p85alpha-iSH 2 structure ( ) .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(21, 0), 'end':(21, 17), 'text':'In the WT apo p110alpha and p85alpha-iSH 2 structure , helix kalpha11 is complete to residue 1048 ,'}, {'start':(21, 18), 'end':(21, 43), 'text':'and the rest of the C-terminal sequence is largely disordered ( ) [ hereafter all p110 secondary structure nomenclature is according to that of p110gamma .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 23), 'text':'The kinase C-terminal tail in our structure adopts an extended conformation from residue 1045 to 1061 , with the last helical turn of kalpha11'}, {'start':(22, 24), 'end':(22, 30), 'text':'appearing to be distorted ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 9), 'text':'A striking feature in this region is the WIF motif'}, {'start':(23, 10), 'end':(23, 13), 'text':'( 1057-1059 ) ,'}]}, {'start':(23, 14), 'end':(23, 22), 'text':'whose side-chains stack against each other ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 19), 'text':'This motif is conserved as a triplet of hydrophobic residues in class I and class II PI3Ks , with W1057'}, {'start':(24, 20), 'end':(24, 28), 'text':'being invariant in class I p110 ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 17), 'text':'The equivalent \' WFL \' ( 1086-1088 ) in p110gamma is part of helix kalpha12 ( ) ,'}, {'start':(25, 18), 'end':(25, 25), 'text':'which corresponds to residues 1050-1061 in p110alpha .'}]}, {'start':(26, 0), 'end':(26, 12), 'text':'Helix kalpha12 also exists in the crystal structures of p110beta and Vps34 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(27, 0), 'end':(27, 17), 'text':'This C-terminal region in our structure , and also in the H1047R p110alpha and p85alpha-niSH 2 structures ,'}, {'start':(27, 18), 'end':(27, 38), 'text':'is involved in crystal packing with the Ras binding domain ( RBD ) of a symmetry related molecule ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 21), 'text':'Therefore , the conformations of the C-terminal tail among the current p110alpha structures appear to be dictated by the crystalline environments .'}, {'start':(29, 0), 'end':(29, 21), 'text':'It is likely fortuitous that the RBD and the kinase domain pack against each other in different crystal forms of p110alpha .'}]}, {'start':(30, 0), 'end':(30, 18), 'text':'We would not ascribe any functional significance to these crystal contacts , particularly with regard to Ras activation .'}]}]}]}, {'start':(31, 0), 'end':(31, 17), 'text':'Deletion of helix kalpha12 in Vps34 , p110beta and p110delta abrogated lipid kinase activity and lipid binding .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 8), 'text':'This region is also of functional importance for p110alpha'}, {'start':(32, 9), 'end':(32, 13), 'text':'( see below ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 22), 'text':'Deletion of kalpha12 in Vps34 and in p110beta resulted in increased intrinsic ATPase activity in the absence of lipid substrate , an observation'}, {'start':(33, 23), 'end':(33, 32), 'text':'replicated by deletion of residues 1051-1068 in p110alpha ( ,'}]}, {'start':(33, 33), 'end':(33, 36), 'text':'Deltacterm mutant ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 7), 'text':'Interactions between helix kalpha12 and the catalytic loop'}, {'start':(34, 8), 'end':(34, 13), 'text':'( illustrated for p110gamma in )'}]}, {'start':(34, 14), 'end':(34, 28), 'text':'were suggested to shield the conserved catalytic DRH motif from performing futile ATP hydrolysis .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 11), 'text':'These interactions are not observed in the current p110alpha crystal structures ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(35, 12), 'end':(35, 12), 'text':'suggesting'}, {'start':(35, 13), 'end':(35, 32), 'text':'that in solution , p110alpha could also have a helix kalpha12 , similar to p110gamma , p110beta and Vps34 .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 2), 'text':'The extended conformations'}, {'start':(36, 3), 'end':(36, 17), 'text':'observed in current crystal structures of p110alpha suggest an intrinsic flexibility in this region .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 0), 'end':(37, 7), 'text':'Correlation of lipid kinase activity with lipid binding'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 11), 'text':'To test whether lipid binding forms the basis of p110 activation ,'}, {'start':(38, 12), 'end':(38, 28), 'text':'we compared lipid kinase with lipid binding activities for three sets of p110alpha and p85alpha complexes :'}]}, {'start':(38, 29), 'end':(38, 52), 'text':'SH2 deletions in p85alpha , engineered mutations in the p110alpha kinase domain and cancer linked mutations in both p110alpha and p85alpha ( ) .'}]}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 9), 'text':'We evaluated activation by RTK phosphopeptide for all complexes ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 10), 'end':(39, 18), 'text':'using the doubly tyrosine phosphorylated peptide ( pY2-peptide )'}, {'start':(39, 19), 'end':(39, 22), 'text':'derived from PDGFRbeta .'}]}]}]}]}]}, {'start':(40, 0), 'end':(40, 14), 'text':'We used liposomes of defined compositions generally mimicking that of plasma membranes ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(41, 0), 'end':(41, 20), 'text':'The substrate PtdIns ( 4,5 ) P 2 was used at 2 % ( close to the physiological concentration ) ,'}, {'start':(41, 21), 'end':(41, 40), 'text':'and the anionic lipid phosphatidylserine ( PS ) was tested at two concentrations , 10 % and 20 % .'}]}, {'start':(42, 0), 'end':(42, 18), 'text':'Cancer linked mutations and nSH2 deletion in p85alpha severely suppressed expression of p110 and p85 in insect cells .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(43, 0), 'end':(43, 8), 'text':'To obtain sufficient materials for lipid binding analyses ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 9), 'end':(43, 24), 'text':'we produced activating p110alpha and p85alpha proteins in the catalytically dead ( CD ) background ,'}, {'start':(43, 25), 'end':(43, 36), 'text':'bearing the D915N mutation in the catalytic DRH motif of p110alpha .'}]}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 4), 'text':'We employed surface plasmon resonance'}, {'start':(44, 5), 'end':(44, 7), 'text':'( SPR )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 8), 'end':(44, 11), 'text':'to measure lipid binding'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 12), 'end':(44, 13), 'text':'( schematics'}, {'start':(44, 14), 'end':(44, 17), 'text':'shown in ) .'}]}]}]}]}]}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 12), 'text':'We examined the electrostatic and the hydrophobic components of lipid binding explicitly ,'}, {'start':(45, 13), 'end':(45, 23), 'text':'since both are important properties for many membrane binding proteins .'}]}]}, {'start':(46, 0), 'end':(46, 19), 'text':'We immobilized liposomes of different compositions in each of the four serially connected flow cells on the sensor chip .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(47, 0), 'end':(47, 24), 'text':'Flow cell one ( Fc1 ) of the chip contained only neutral lipids phosphatidylcholine ( PC ) , phosphatidylethanolamine ( PE ) and cholesterol ,'}, {'start':(47, 25), 'end':(47, 55), 'text':'while Fc2 , Fc3 and Fc4 contained additionally negatively charged lipids PS ( Fc2 ) , or PS with PtdIns ( 4,5 ) P 2 ( Fc3 and Fc4 ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 5), 'text':'As such , Fc1 subtracted signals'}, {'start':(48, 6), 'end':(48, 12), 'text':'represent the electrostatic component of binding .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 0), 'end':(49, 6), 'text':'We attribute any binding signals on Fc1'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 7), 'end':(49, 19), 'text':'that are significantly above background ( estimated as the averaged signal on Fc1'}, {'start':(49, 20), 'end':(49, 27), 'text':'produced by the lipid kinase dead mutants )'}]}, {'start':(49, 28), 'end':(49, 36), 'text':'to be the hydrophobic component of lipid binding .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 0), 'end':(50, 16), 'text':'p85alpha nSH2 , but not cSH2 , regulates both lipid kinase activity and membrane binding of p110alpha'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 5), 'text':'The nSH2 plays a dominant role'}, {'start':(51, 6), 'end':(51, 14), 'text':'in regulating the lipid kinase activity of p110alpha .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 19), 'text':'The basal activities of p110alpha and p85alpha-nicSH 2 and p110alpha and p85alpha-niSH 2 complexes are very low using liposome substrate'}, {'start':(52, 20), 'end':(52, 32), 'text':'mimicking physiological concentrations of PS and PtdIns ( 4,5 ) P 2 .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 9), 'text':'Activation , whether by binding of RTK phosphopeptide to nSH2'}, {'start':(53, 10), 'end':(53, 17), 'text':'containing complexes , or by nSH2 deletion ,'}]}, {'start':(53, 18), 'end':(53, 26), 'text':'increases the activity by 25-50 fold ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 8), 'text':'Qualitatively , our results recapitulate those of previous studies'}, {'start':(54, 9), 'end':(54, 20), 'text':'performed with pure phosphatidylinositol ( PtdIns ) as substrate ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 0), 'end':(55, 6), 'text':'Correspondingly , RTK phosphopeptide binding to nSH2'}, {'start':(55, 7), 'end':(55, 14), 'text':'containing complexes induces lipid binding ( ) .'}]}]}]}, {'start':(56, 0), 'end':(56, 18), 'text':'Binding of RTK phosphopeptide to cSH2 does not affect either the kinase activity or membrane binding ( ) .'}]}, {'start':(57, 0), 'end':(57, 10), 'text':'Total negative charge on the liposomes positively influenced lipid binding .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(58, 0), 'end':(58, 1), 'text':'Liposome compositions'}, {'start':(58, 2), 'end':(58, 17), 'text':'differing by 10 % in PS confer up to two-fold increases in lipid binding levels .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(59, 0), 'end':(59, 3), 'text':'Hence , it appears'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 4), 'end':(59, 12), 'text':'that for p110alpha , the nSH2-p110alpha inhibitory contact ,'}, {'start':(59, 13), 'end':(59, 19), 'text':'which is relieved by phosphopeptide binding ,'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(59, 20), 'end':(59, 25), 'text':'suppresses the basal lipid kinase activity'}, {'start':(59, 26), 'end':(59, 30), 'text':'by inhibiting membrane binding .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 0), 'end':(60, 13), 'text':'Both kinase activation loop and C-terminal tail are necessary for binding to anionic lipids'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(61, 0), 'end':(61, 17), 'text':'Using PtdIns ( 4,5 ) P 2 -containing liposomes , no kinase activity could be detected for three'}, {'start':(61, 18), 'end':(61, 22), 'text':'engineered kinase domain mutants :'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(61, 23), 'end':(61, 40), 'text':'( i ) the activation loop mutant R949D , ( ii ) the kinase helix kalpha12 deletion mutant'}, {'start':(61, 41), 'end':(61, 44), 'text':'( Deltacterm ) ,'}]}, {'start':(61, 45), 'end':(61, 80), 'text':'nor ( iii ) a helix kalpha12 triple mutant with much reduced hydrophobicity ( WIF-AAA ( 1057-1059 ) ) , with protein concentration as high as 500 nM and incubation time up to an hour .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 0), 'end':(62, 16), 'text':'These mutants , however , are catalytically active in terms of intrinsic ATPase activity ( ) .'}, {'start':(63, 0), 'end':(63, 19), 'text':'In lipid binding experiments , correspondingly , the R949D mutant showed much reduced binding to anionic lipids ( ) .'}]}, {'label':'evaluation', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 0), 'end':(64, 8), 'text':'The same result was observed for K942Q ( data'}, {'start':(64, 9), 'end':(64, 12), 'text':'not shown ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(65, 0), 'end':(65, 6), 'text':'These results are consistent with the observation'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(65, 7), 'end':(65, 8), 'text':'that mutations'}, {'start':(65, 9), 'end':(65, 32), 'text':'removing the positive charges of the equivalent residues in p110gamma prevent PtdIns ( 4,5 ) P 2 , but not PtdIns or PtdIns4P ,'}]}, {'start':(65, 33), 'end':(65, 40), 'text':'from acting as a substrate ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(66, 0), 'end':(66, 25), 'text':'The kinase C terminal mutants , Deltacterm and WIF-AAA , did not show any detectable binding to anionic lipids at concentration up to 1 muM .'}, {'start':(67, 0), 'end':(67, 16), 'text':'This establishes the WIF motif as a key determinant for lipid binding in the C-terminal region .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(68, 0), 'end':(68, 2), 'text':'These results indicate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(68, 3), 'end':(68, 16), 'text':'that there are at least two lipid binding sites in the kinase domain :'}, {'start':(68, 17), 'end':(68, 40), 'text':'one is in the polybasic activation loop , electrostatic in nature , and the other in the C-terminal region , hydrophobic in nature .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 0), 'end':(69, 2), 'text':'Effects of cancer'}, {'start':(69, 3), 'end':(69, 11), 'text':'linked mutations in p110alpha and p85alpha on lipid binding'}]}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(70, 0), 'end':(70, 12), 'text':'To gain a broader view of the effects of cancer linked mutations ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(70, 13), 'end':(70, 16), 'text':'we studied seven mutations'}, {'start':(70, 17), 'end':(70, 25), 'text':'that have previously been characterized to be activating .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(71, 0), 'end':(71, 42), 'text':'They cover three structurally distinct regions ( ) , namely , the C2-iSH2 interface ( p110alpha C420R and p85alpha N564D ) , the helical-nSH2 interface ( p110alpha E545K ) and the kinase domain ( M1043I , H1047L , H1047R and G1049R ) ,'}, {'start':(71, 43), 'end':(71, 49), 'text':'and represent different chemical property changes .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(72, 0), 'end':(72, 25), 'text':'Overall , there is a strong correlation between lipid kinase activity and lipid binding ( , total lipid binding on Fc4 is shown in ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(72, 26), 'end':(72, 35), 'text':'underscoring enhanced lipid binding as a general mechanism for cancer'}, {'start':(72, 36), 'end':(72, 39), 'text':'linked activating mutations .'}]}]}]}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(73, 0), 'end':(73, 11), 'text':'All mutants have increased basal activity , and other than E545K ,'}, {'start':(73, 12), 'end':(73, 20), 'text':'can be significantly further activated by phosphopeptide binding .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(74, 0), 'end':(74, 1), 'text':'This affirms'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(74, 2), 'end':(74, 17), 'text':'that the C2-iSH2 inhibitory contact site does not function identically to the nSH2 inhibitory site ,'}, {'start':(74, 18), 'end':(74, 31), 'text':'which includes both C2 and helical domains in the crystal structure ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 0), 'end':(75, 14), 'text':'The degree of activation is enhanced by increase in negative charges on the liposomes .'}, {'start':(76, 0), 'end':(76, 14), 'text':'Both anionic lipids PS and PtdIns ( 4,5 ) P 2 enhance lipid binding .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(77, 0), 'end':(77, 3), 'text':'There is a pattern'}, {'start':(77, 4), 'end':(77, 19), 'text':'correlating the location of the mutations with their hydrophobic component of lipid binding ( ) :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(77, 20), 'end':(77, 44), 'text':'non kinase domain mutants ( C420R , E545K and p85alpha-N564D ) display high levels of hydrophobic interaction with neutral lipids in the basal state ,'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(77, 45), 'end':(77, 53), 'text':'whereas the kinase C terminal mutants require phosphopeptide activation'}, {'start':(77, 54), 'end':(77, 62), 'text':'to achieve the same level of hydrophobic binding .'}]}]}]}, {'start':(78, 0), 'end':(78, 7), 'text':'We will consider the two groups separately .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 0), 'end':(79, 45), 'text':'Despite their different chemical properties , the kinase domain mutants , H1047L , H1047R and G1049R , exhibit similarly high levels of hydrophobic binding to neutral lipids , and electrostatic binding to PS and PtdIns ( 4,5 ) P 2 -containing lipids upon phosphopeptide activation .'}, {'start':(80, 0), 'end':(80, 15), 'text':'These binding levels are a few fold higher than those of the activated WT enzyme .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(81, 0), 'end':(81, 2), 'text':'We have shown'}, {'start':(81, 3), 'end':(81, 13), 'text':'that the kinase helix kalpha12 constitutes a lipid binding site .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 0), 'end':(82, 12), 'text':'It is likely that helix kalpha11 and the kalpha11-kalpha12 " elbow " ,'}, {'start':(82, 13), 'end':(82, 18), 'text':'on which these mutations reside ,'}]}, {'start':(82, 19), 'end':(82, 26), 'text':'is an extension of the same site .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(83, 0), 'end':(83, 17), 'text':'For non kinase domain mutants , the nature of the effects of hydrophobicity is not immediately obvious .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(84, 0), 'end':(84, 26), 'text':'Disruption of the C2-iSH2 ( C420R and p85alpha-N564D ) or the C2 and helical-nSH 2 contacts ( E545K ) could expose hydrophobic regions in the C2 domain'}, {'start':(84, 27), 'end':(84, 34), 'text':'that are normally inaccessible to lipid binding .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(85, 0), 'end':(85, 10), 'text':'The iSH2 N564 forms polar contacts with the C2 N345 ,'}, {'start':(85, 11), 'end':(85, 17), 'text':'which is in the C2beta1-beta2 loop .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(86, 0), 'end':(86, 3), 'text':'The C2 C420 ,'}, {'start':(86, 4), 'end':(86, 10), 'text':'which is in the C2beta5-beta6 loop ,'}]}, {'start':(86, 11), 'end':(86, 21), 'text':'forms van der Waals contacts with iSH2 P568 ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(87, 0), 'end':(87, 19), 'text':'These two C2 loops in p110alpha are equivalent to the lipid binding loops in the C2 domains of PKCalpha ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(87, 20), 'end':(87, 30), 'text':'which binds PS ( ) , and of cPLA 2 ,'}, {'start':(87, 31), 'end':(87, 34), 'text':'which binds PC .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(88, 0), 'end':(88, 6), 'text':'Superposition of the PKCalpha C2 structure ,'}, {'start':(88, 7), 'end':(88, 18), 'text':'which has a bound short acyl-chain PS molecule ( PDB ID :'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(88, 19), 'end':(88, 33), 'text':'1dsy ) , onto the C2 domain of our p110alpha and p85alpha-iSH 2 structure reveals'}, {'start':(88, 34), 'end':(88, 48), 'text':'that both N564D and C420R would be compatible with accessing phospholipid headgroups ( ) .'}]}]}, {'start':(89, 0), 'end':(89, 16), 'text':'This interpretation would account for the observed increase in electrostatic interaction with anionic lipids ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(90, 0), 'end':(90, 7), 'text':'Global conformational change in p110alpha accompanies nSH2 disengagement'}, {'label':'contrast', 'direction':'None', 'children':[{'start':(91, 0), 'end':(91, 15), 'text':'The p85alpha nSH2 does not contact the lipid binding elements in the kinase C-lobe ( )'}, {'start':(91, 16), 'end':(91, 26), 'text':'but appears to control their access to membrane ( ) .'}]}]}]}, {'start':(92, 0), 'end':(92, 10), 'text':'This suggests the activation mechanism by nSH2 to be allosteric .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'RightToLeft', 'children':[{'start':(93, 0), 'end':(93, 12), 'text':'By performing structural alignments on the iSH2 of p110alpha and p85alpha structures ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(93, 13), 'end':(93, 20), 'text':'we observe a global conformational difference between those'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(93, 21), 'end':(93, 27), 'text':'lacking the inhibitory contacts with nSH2 ('}, {'label':'joint', 'direction':'None', 'children':[{'start':(93, 28), 'end':(93, 38), 'text':'as represented by the WT p110alpha and p85alpha-iSH 2 structures )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(93, 39), 'end':(93, 44), 'text':'and those with the nSH2 interactions'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(93, 45), 'end':(93, 45), 'text':'('}, {'start':(93, 46), 'end':(93, 59), 'text':'as represented by the H1047R p110alpha and p85alpha-niSH 2 structures ) ( ) .'}]}]}]}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(94, 0), 'end':(94, 3), 'text':'Viewing down the iSH2'}, {'start':(94, 4), 'end':(94, 11), 'text':'coiled coil axis from the nSH2 side ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(94, 12), 'end':(94, 26), 'text':'the p110alpha subunit rotates clockwise from the state with an ordered nSH2 to the state'}, {'start':(94, 27), 'end':(94, 32), 'text':'lacking the nSH2 ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(95, 0), 'end':(95, 5), 'text':'The ABD and the C2 ,'}, {'start':(95, 6), 'end':(95, 12), 'text':'which are anchored on the iSH2 ,'}]}, {'start':(95, 13), 'end':(95, 22), 'text':'form the pivot points of the movement ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(96, 0), 'end':(96, 17), 'text':'The movement appears to be transmitted from the helical domain to the RBD and the kinase C-lobe ,'}, {'start':(96, 18), 'end':(96, 27), 'text':'which exhibit the greatest degree of displacement ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(97, 0), 'end':(97, 4), 'text':'This global conformational change suggests'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(97, 5), 'end':(97, 19), 'text':'how nSH2 disengagement from p110alpha could allosterically cause local conformational change in the kinase C-lobe'}, {'start':(97, 20), 'end':(97, 25), 'text':'that might impact on activity .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(98, 0), 'end':(98, 3), 'text':'This is noteworthy considering'}, {'start':(98, 4), 'end':(98, 35), 'text':'that our WT p110alpha and p85alpha-iSH 2 and PIK -108 structure and the apo WT p110alpha and p85alpha-iSH 2 structure experience very different crystal packing environments but superimpose well ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(99, 0), 'end':(99, 10), 'text':'Activation of all class IA PI3Ks by phosphopeptide increases lipid binding'}, {'start':(100, 0), 'end':(100, 20), 'text':'Activation of p110beta and p85alpha-nicSH 2 and p110delta and p85alpha-nicSH 2 complexes by phosphopeptide also induces lipid binding ( ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(101, 0), 'end':(101, 18), 'text':'This is in agreement with the recent report for p110delta in a complex with full-length p85alpha ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(102, 0), 'end':(102, 16), 'text':'The relative contributions of electrostatic and hydrophobic components of binding differ among the three p110 isoforms ,'}, {'start':(102, 17), 'end':(102, 30), 'text':'probably reflecting their sequence variability in the key lipid binding sites ( ) .'}]}, {'start':(103, 0), 'end':(103, 18), 'text':'In the primary sequences , the equivalent of H1047 in p110alpha is a Leu in p110beta and p110delta .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(104, 0), 'end':(104, 11), 'text':'For PS and PtdIns ( 4,5 ) P 2 -containing liposomes ,'}, {'start':(104, 12), 'end':(104, 35), 'text':'the total lipid binding level of activated H1047L p110alpha is a few fold higher than those of activated p110beta and p110delta ( ) .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(105, 0), 'end':(105, 2), 'text':'These results indicate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(105, 3), 'end':(105, 10), 'text':'that there is more than this hotspot position'}, {'start':(105, 11), 'end':(105, 22), 'text':'that differentiates the lipid binding capabilities among the three p110 isoforms .'}]}]}]}]}]}]}
